- Home
- PASW vs AYTU Comparison
PASW vs AYTU Comparison
Compare PASW & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASW
- AYTU
- Stock Information
- Founded
- PASW 2021
- AYTU N/A
- Country
- PASW Hong Kong
- AYTU United States
- Employees
- PASW N/A
- AYTU N/A
- Industry
- PASW Apparel
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- PASW Consumer Discretionary
- AYTU Health Care
- Exchange
- PASW Nasdaq
- AYTU Nasdaq
- Market Cap
- PASW 20.3M
- AYTU 18.8M
- IPO Year
- PASW N/A
- AYTU N/A
- Fundamental
- Price
- PASW $1.01
- AYTU $2.33
- Analyst Decision
- PASW
- AYTU Strong Buy
- Analyst Count
- PASW 0
- AYTU 3
- Target Price
- PASW N/A
- AYTU $9.17
- AVG Volume (30 Days)
- PASW 2.8M
- AYTU 381.3K
- Earning Date
- PASW 11-15-2025
- AYTU 11-12-2025
- Dividend Yield
- PASW N/A
- AYTU N/A
- EPS Growth
- PASW N/A
- AYTU N/A
- EPS
- PASW N/A
- AYTU N/A
- Revenue
- PASW $8,286,193.00
- AYTU $66,382,000.00
- Revenue This Year
- PASW N/A
- AYTU N/A
- Revenue Next Year
- PASW N/A
- AYTU $19.03
- P/E Ratio
- PASW N/A
- AYTU N/A
- Revenue Growth
- PASW N/A
- AYTU 1.84
- 52 Week Low
- PASW $0.89
- AYTU $0.95
- 52 Week High
- PASW $5.40
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- PASW N/A
- AYTU 55.70
- Support Level
- PASW N/A
- AYTU $1.65
- Resistance Level
- PASW N/A
- AYTU $1.98
- Average True Range (ATR)
- PASW 0.00
- AYTU 0.16
- MACD
- PASW 0.00
- AYTU 0.01
- Stochastic Oscillator
- PASW 0.00
- AYTU 64.35
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.